Infliximab concentration monitoring improves the control of disease activity in rheumatoid arthritis

• Published in: Arthritis research & therapy 2009-01, Vol.11 (6), p.R178-R178, Article R178
• Main Authors: Mulleman, Denis, Méric, Jean-Camille, Paintaud, Gilles, Ducourau, Emilie, Magdelaine-Beuzelin, Charlotte, Valat, Jean-Pierre, Goupille, Philippe
• Format: Article
• Language: English
• Subjects: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal - administration & dosage; Antibodies, Monoclonal - blood; Antirheumatic Agents; Antirheumatic Agents - administration & dosage; Antirheumatic Agents - blood; Arthritis, Rheumatoid; Arthritis, Rheumatoid - blood; Arthritis, Rheumatoid - drug therapy; Complications and side effects; Dosage and administration; Drug Administration Schedule; Drug Monitoring; Drug Monitoring - methods; Drug therapy; Drugs; Female; Health aspects; Human health and pathology; Humans; Infliximab; Life Sciences; Male; Middle Aged; Patient outcomes; Rheumatoid arthritis; Rhumatology and musculoskeletal system
• ISSN: 1478-6354; 1478-6362; 1478-6354
• DOI: 10.1186/ar2867

Adjustment of infliximab dosage for individuals may be useful in improving therapeutic response in rheumatoid arthritis (RA). Herein, we aimed to determine whether measurement of infliximab serum concentration modifies the therapeutic decision and improves the control of disease activity. RA patients routinely treated with infliximab were included in an observational open-label study. On visit 1 (V1), according to the disease activity, a preliminary therapeutic decision was selected among four therapeutic options and a blood sample was collected to measure trough serum infliximab concentration. The final therapeutic decision, based on both disease activity and serum infliximab concentration assessed at V1, was applied at the following infusion (V2). Clinical and biological evaluations were performed at V3 and V4 and compared with those at V1. We included 24 patients. The final therapeutic decision differed from the preliminary decision for 12 patients (50%). For patients with increased infliximab dosage at V2, mean disease activity score for 28 joints (DAS28) decreased by about 20% at V3 or V4 as compared with V1 (P < 0.05). Decreased DAS28 was correlated with increased serum infliximab concentration (P < 0.02). The measurement of infliximab trough concentration modifies the therapeutic decision for RA patients and helps improve control of disease activity. Therapeutic drug monitoring of infliximab in RA may be useful for individual dosage adjustment.